InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 198569

Friday, 12/05/2014 10:24:02 AM

Friday, December 05, 2014 10:24:02 AM

Post# of 345952
nice post CP re: PPHM history and I still can't believe all those that continue to not see the intrinsic value, which will become astronomical in value.

Blood based biomarkers and exactly what happens to all those proteins (MDSC's..) when PS is targeted is the key I believe.

I hope Tustin has plans to set up a parallel lab to simply study all FDA approved immunotherapy agents and watch what happens, because some of the data may not make it to the FDA to properly explain a drugs MOA. I know... I'm already thinking of what could happen but better to be prepared.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News